Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
- DOI
- 10.1016/s1470-2045(26)00194-4
- Published
- 2026 Aug
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-26-00194-4,
title = {Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.},
author = {Tyson MD 2nd and Nam JK and Joshi SS and Uchio EM and Jung SI and Bivalacqua TJ and Steinberg GD and Shore ND and Burke JM and Kitamura H and Tran B and Li R},
year = {2026},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(26)00194-4},
url = {https://doi.org/10.1016/s1470-2045(26)00194-4}
}RIS
TY - JOUR TI - Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial. AU - Tyson MD 2nd AU - Nam JK AU - Joshi SS AU - Uchio EM AU - Jung SI AU - Bivalacqua TJ AU - Steinberg GD AU - Shore ND AU - Burke JM AU - Kitamura H AU - Tran B AU - Li R PY - 2026 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(26)00194-4 UR - https://doi.org/10.1016/s1470-2045(26)00194-4 ER -
APA
2nd, T. M., JK, N., SS, J., EM, U., SI, J., TJ, B., GD, S., ND, S., JM, B., H, K., B, T., & R, L. (2026). Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00194-4
Source records
- pubmed · retrieved 2026-09-26T06:51:00.223Z
- europe-pmc · retrieved 2026-09-26T06:51:00.236Z